FDA approves Moderna’s mRNA flu vaccine

The FDA has approved Moderna’s mFLUSIVA (mRNA-1010), the first mRNA-based influenza vaccine in the U.S., for the prevention of seasonal influenza in adults ages 50 and older. The decision follows a monthslong regulatory process that included the agency’s initial refusal to review the application, a subsequent reversal and a unanimous recommendation from an FDA advisory […] The post FDA approves Moderna’s mRNA flu vaccine appeared first on Becker's Hospital Review | H...